| Literature DB >> 17786216 |
Imad J Matouk1, Nathan DeGroot, Shaul Mezan, Suhail Ayesh, Rasha Abu-lail, Abraham Hochberg, Eithan Galun.
Abstract
BACKGROUND: Mutations and epigenetic aberrant signaling of growth factors pathways contribute to carcinogenesis. Recent studies reveal that non-coding RNAs are controllers of gene expression. H19 is an imprinted gene that demonstrates maternal monoallelic expression without a protein product; although its expression is shut off in most tissues postnatally, it is re-activated during adult tissue regeneration and tumorigenesis. Moreover, H19 is highly expressed in liver metastasis derived from a range of carcinomas. The objective of this study is to explore the role of H19 in carcinogenesis, and to determine its identification as an anti-tumor target. METHODOLOGY/PRINCIPLEEntities:
Mesh:
Substances:
Year: 2007 PMID: 17786216 PMCID: PMC1959184 DOI: 10.1371/journal.pone.0000845
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1H19 RNA is largely induced in response to hypoxic stress and moderately by hypoxia-mimicking condition triggered by CoCl2 in Hep3B.
Hep3B cells were cultured under normal culture conditions for 24 hours before hypoxic or CoCl2 manipulation. Cells were either placed into an aneoropack rectangular jar to create a hypoxic condition within an hour, or left under normal culture conditions. Incubation lasted for 24 hours before RNA extraction. (A) Shown are RT-PCR products of H19 gene (28 PCR cycles) cultured under normal conditions-lane 1, or hypoxic conditions-lane 2 (lane M indicates the marker, and C is a PCR blank without a target). (B) PCR for Histone H3.3 as a positive control for RT-PCR integrity. Shown also are RT-PCR products of both the H19 gene (32 PCR cycles) (C), the GAPDH gene (D) for untreated Hep3B (lane1) and for 50, 100, 200, 300 and 400 µM CoCl2 treated cells (lanes 2, 3, 4, 5 and 6, respectively). Incubation with the indicated concentrations of CoCl2 lasted for an additional 22 hours before RNA extraction. QPCR analysis for H19 RNA levels normalized to β-actin in Hep3B treated CoCl2 is shown in (E) where the numbers above the bars indicate the concentrations of CoCl2 used.
Figure 2Effect of four different H19 siRNA duplexes on the expression level of H19 in the Hep3B cell line under normal culture condition (A) and hypoxia-mimicking CoCl2 treatment (B).
Shown is H19 RNA levels (34 PCR cycles) in (A): Hep3B cells transfected with unrelated siRNA duplex that targets luciferase gene (lane 1) and with 4 different H19 siRNA1 to H19 siRNA4 duplexes (lanes 2–5) and an equimolar mixture of the four siRNAs (lane 6); for controls, we performed transfection also with lipofectamine 2000 without siRNA (Mock) (lane 7) and C is PCR blank without a target. (B): Hep3B cells were transfected under normal medium with siRNA duplex that targets the luciferase gene (lanes 1 and 5) and with 3 different H19 siRNA duplexes (lanes 2–4). Twenty four hours post transfection, media was changed, and 100 µM CoCl2 containing media was added except for lane 5 which continued to grow under normal culture media; the incubation lasted for an additional 22 hours. (C): Shown are RT-PCR products of GAPDH gene as a positive control for RT-PCR integrity.
Figure 3H19 RNA is induced by hypoxic stress in Hep3B cell line and siRNA directed against H19 very efficiently impedes its induction.
Hep3B cells were seeded and transfected either with H19 siRNA or luc siRNA . Twenty four hours post transfection, cells were either placed into an aneoropack rectangular jar , or left under normal oxygen concentration. Incubation lasted for 24 hours before RNA extraction. Shown are RT-PCR analyses for H19 RNA (28 PCR cycles). (A): Hep3B transfected with Luc siRNA (lanes 1, 2) and H19 siRNA (lanes 3, 4) both in normal (lanes 1, 3) and hypoxic (lanes 2, 4) culture conditions, respectively. PCR analysis of a house-keeping gene Histone H3.3 (B), and uPAR (C). In (D) QPCR analysis for H19 RNA levels normalized to β-actin in Hep3B cells is depicted.. A Quantitative SYBR Green RT–PCR was performed on human total RNA for both H19 and β-actin to estimate H19 RNA copy number under different manipulations and efficiency of knockdown under hypoxic conditions.
Figure 4Transient H19 RNA knockdown in Hep3B cells inhibited tumorigenicity in vivo.
Hep3B cells were transiently transfected with H19 siRNA3 or Luc siRNA. Forty eight hours post transfection, cells were washed twice with PBS, trypsinized and counted. Equal numbers of cells (1.5×106) were injected subcutaneously into the dorsal part of CD-1 nude mice (n = 7 for both, and 4 for mock transfected). Palpable tumors were observed 15 days post inoculation in mice inoculated with Hep3B, transiently transfected with Luc siRNA. Tumor volumes were followed up and measured using a caliper until day 30 post inoculation, after which mice were sacrificed. Significant (p<0.03) reductions of about 82% of both mean tumor weights (A) (± standard error) and mean tumor volumes (p<0.03) (B) (± standard error) were observed. Values represent end-points just before and after sacrificing animals. Shown are also representative features of tumors in 2 mice of each group (mice 1 and 2 are the H19 siRNA3 treated Hep3B cells, and mice 3 and 4 are the Luc siRNA ) before tumor surgical exposure (C), and after exposure of their internal tumors (D).
Figure 5The effect of over-expression of H19 RNA on the tumorigenic potential of bladder carcinoma cells in vivo.
Equal amounts (2×106) of TA31H19high and TA11H19-ve cells were implanted subcutaneously to CD-1 mice (n = 5, each). Two weeks later, palpable tumors appeared and tumor volumes were measured for an additional two weeks . Shown are end point measurements of the mean tumor volumes of the two groups (upper left pannel), their mean tumor volumes kinetics (upper right), and a representative gross morphology of tumors derived from the TA11H19-ve (lower left) and TA31H19high cells(down and right).
Figure 6The in vivo effect of H19 silencing on the tumorigenic potential of human bladder carcinoma cells-UMUC3.
One million UMUC3 cells were injected subcutaneously to athymic mice (n = 3 for GFP siRNA, and 5 for H19 siRNA ), 48 hours after transiently transfected with siRNAs. Palpable tumors were observed 6 weeks later in 2 out of 3 mice of the GFP siRNA group, while in none of the H19 siRNA group . Mice were sacrificed 8 weeks after inoculation. Mean tumor volumes (B, P<0.05), and mean tumor weights (A, p<0.06) are depicted. Values represent end-points just before and after sacrificing animals. Pictures depict the external features of the tumors in mice inoculated with UMUC3 transfected with GFP siRNA (C), and H19 siRNA (D).
Figure 7H19 RNA knockdown impedes p57Kip2 mRNA induction in response to hypoxic stress, in Hep3B cell line.
Hep3B cells were seeded and transfected either with H19 siRNA or Luc siRNA as described . Shown are RT-PCR analyses for H19 RNA (28 PCR cycles). (A): Hep3B transfected with luc siRNA (lanes 1, 2) and H19 siRNA (lanes 3, 4) both in normal (lanes 1, 3) and hypoxic (lanes 2, 4) culture conditions, respectively. And similar treatments are assessing the mRNA levels of: (B). p19INK4 (C). p57Kip2 (D). Histone.
Genes reduced by at least two-folds by H19 knockdown in hypoxic stress.
| Gene Symbol | Gene name | Folds Change | Functional Category |
|
| |||
|
| Tumor necrosis factor, alpha-induced protein 1 (endothelial) | 2.0 | Immune response/angiogenesis |
|
| calponin 2 | 2.1 | Cytoskeleton |
|
| inhibitor of DNA binding 2, dominant negative helix-loop-helix protein | 2.7 | Development |
|
| prolylcarboxypeptidase (angiotensinase C) (not hypoxia) | 2.0 | Proteolysis |
|
| angiogenin | 2.5 | Angiogenesis |
|
| ribonuclease, RNase A family, 4 | 3.0 | mRNA cleavage/Angiogenesis |
|
| fibroblast growth factor 18 | Growth factor activity | |
|
| |||
|
| immediate early response 3 | 2.5 | Anti-apoptosis |
|
| protein kinase C, zeta | 2.2 | Anti-apoptotic |
|
| v-akt murine thymoma viral oncogene homolog 1 | 3.2 | Anti-apoptotic |
|
| microphthalmia-associated transcription factor | 2.1 | Regulation transcription/differentiation |
|
| |||
|
| tubulin, beta 2 | 2.4 | Cytoskeleton |
|
| drebrin 1 | 3.4 | Actin filament organization |
|
| formin homology 2 domain containing 3 | 2.4 | Actin cytoskeleton |
|
| fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus) | 9.0 | Actin cytoskeleton/proliferation |
|
| syntrophin, alpha 1 (dystrophin-associated protein A1, 59kDa, acidic component) | 3.3 | Actin cytoskeleton |
|
| MAP/microtubule affinity-regulating kinase 4 | 3.4 | Microtuble bundle formation |
|
| kinesin family member 3C | 3.0 | Microtubule based movement |
|
| |||
|
| aldehyde dehydrogenase 1 family, member A3 | 2.8 | Metabolism |
|
| Phospholipase A2, group IV (cytosolic, calcium-dependent) | 3.2 | Lipid catabolism |
|
| coronin, actin binding protein, 2A | 2.2 | Nitrogen compounds metabolism |
|
| phospholipid scramblase 4 | 2.0 | Phospholipids scrambling |
|
| isocitrate dehydrogenase 3 (NAD+) alpha | 3.8 | Metabolism |
|
| mannose phosphate isomerase | 4.4 | Carbohydrate metabolism |
|
| alpha-methylacyl-CoA racemase | 2.7 | Metabolism |
|
| |||
|
| Estrogen receptor binding site associated, antigen, 9 | 5.0 | Regulation of cell growth. |
|
| Ras association (RalGDS/AF-6) domain family 2 | 2.0 | Cell cycle-signal transduction. |
|
| B-cell CLL/lymphoma 3 | 2.0 | Proto-oncogene |
|
| thymidylate synthetase | 2.4 | DNA replication |
|
| cyclin E2 | 2.3 | Cell cycle |
|
| |||
|
| TRAF3 interacting protein 2 | 2.6 | Signal transducer activity. |
|
| retinoid X receptor, alpha | 3.1 | Nuclear receptor, transcription activator |
|
| transcription factor 2, hepatic; LF-B3; variant hepatic nuclear factor | 3.3 | Transcription factor |
|
| Jumonji, AT rich interactive domain 2 | 3.8 | Transcription/development |
|
| Interleukin 1 receptor accessory protein | 2.1 | Inflamatory response |
|
| uroplakin 1A | 2.1 | Signal transduction/deffirentiation |
|
| Myeloid differentiation primary response gene (88) | 2.2 | NF-KappaB cascade |
|
| Phosphatidylinositol-4-phosphate 5-kinase, type II, beta | 2.0 | Signal transduction |
|
| catenin, beta interacting protein 1 | 2.3 | Wnt receptor signaling pathway |
|
| Peroxisomal biogenesis factor 11A | 2.3 | Signal transduction |
|
| KIAA1196 | 2.4 | Regulation transcription |
|
| zinc finger protein 189 | 2.2 | Metal ion binding/ Transcription |
|
| |||
|
| Zinc fingure protein 185 (LIM domain) | 2,3 | Metal ion binding |
|
| ubiquitin specific peptidase 3 | 3.4 | Ubiquitin dependent protein catabolism |
|
| RAB4A, member Ras oncogene family | 2.2 | Protein transport |
|
| ATPase type 13A2 | 2.2 | Cation transport/metabolism |
|
| synaptogyrin 3 | 2.6 | Membrane protein |
|
| myotubularin related protein 4 | 2.2 | Phospholipids dephosphorylation |
|
| dystroglycan 1 (dystrophin-associated glycoprotein 1) | 2.1 | Laminin receptor activity |
|
| glycolipid transfer protein | 2.1 | Glycolipid transport |
|
| RAD23 homolog B (S. cerevisiae) | 2.1 | Nucleotide-exision repair |
|
| inositol polyphosphate-5-phosphatase, 40kDa | 2.4 | Hydrolase activity/ Cell comunication |
|
| syntaphilin | 2.5 | Synaptic vesicle docking |
|
| FK506 binding protein 9, 63 kDa | 2.8 | Protein folding |
|
| 'tumor protein D52 | 3.0 | Secretion/deffirentiation |
|
| |||
|
| KIAA0802 | 2.0 | |
|
| DENN/MADD domain containing 3 | 2.4 | Unknown |
|
| zinc finger protein 668 | 2.0 | Unknown |
|
| KIAA0802 | 3.8 | Unknown |
|
| KIAA1598 | 2.8 | Unknown |
| Hypothetical protein LOC221362 | 2.9 | Unknown |
= Hypoxia non-responsive, but shows decreased expression by H19 knockdown under hypoxic conditions
Genes induced by at least two-folds by H19 knockdown under hypoxic stress.
| Gene Symbol | Gene name | Folds Change | Functional Category |
|
| |||
| CYLD | cylindromatosis (turban tumor syndrome) | 3.1 | Cell cycle |
| MTUS1 | mitochondrial tumor suppressor 1 | 3.2 | Receptor activity |
| PLK2 | polo-like kinase 2 (Drosophila) | 2.0 | Signal transducer |
| RGS2 | regulator of G-protein signalling 2, 24kDa | 2.8 | Signal transduction |
| CAV1 | caveolin 1, caveolae protein, 22kDa | 2.4 | Cholestrol hemeostasis |
| BTG3 | BTG family member 3 | 3.6 | Antiproliferative |
| TRIB1 | tribbles homolog 1 (Drosophila) | 6.9 | Regulation MAPK activity |
|
| |||
| EFNA1 | ephrin-A1 | 3.9 | Ephrin receptor binding |
| ANGPTL4 | Angiopoietin-like 4 | 2.4 | Angiogenesis/metabolism |
|
| |||
| DDIT3 | DNA-damage-inducible transcript 3 | 4.0 | Growth arrest/apoptosis |
| CASP3 | Caspase 3 | 2.7 | Apoptosis |
|
| |||
| PYGB | Phosphorylase, glycogen; brain | 2.6 | Carbohydrate metabolism |
| SREBF1 | sterol regulatory element binding transcription factor 1 | 2.6 | Metabolism |
| GPD1L | glycerol-3-phosphate dehydrogenase 1-like | 2.0 | Metabolism |
| SMS | Spermine synthase | 2.1 | Polyamine metabolism |
| UAP1 | UDP-N-acteylglucosamine pyrophosphorylase 1 | 4.6 | Metabolism |
|
| |||
| SNAPC1 | small nuclear RNA activating complex, polypeptide 1, 43kDa | 2.2 | Transcription |
| TSN | Translin | 2.0 | DNA recombination |
| RNMT | RNA (guanine-7-) methyltransferase | 4.4 | mRNA capping |
| C10orf10 | C10orf10 | 2.5 | Fasting induced |
| MAPK6 | mitogen-activated protein kinase 6 | 3.4 | Signal transduction |
| C1orf9 | C1orf9 | 2.1 | Transmembrane protein |
| NUPL1 | Nucleoporin like 1 | 3.7 | Transport |
| TMEM2 | Transmembrane protein 2 | 4.6 | Transmembrane protein |
|
| |||
| hypothetical protein DKFZp762E1312 | 2.4 | Unknown | |
| hypothetical protein FLJ13611 | 2.3 | Unknown | |
| COL13A1 | collagen, type XIII, alpha 1 | 2.6 | Unknown |
= Hypoxia non-responsive, but shows decreased expression by H19 knockdown under hypoxic conditions
Figure 8Expression levels of selected genes in Hep3B cells transfected either with H19 and GFP siRNAs under normoxic and hypoxic conditions.
A few genes that showed variations as a result of H19 knockdown under different manipulations were selected, based on their potential importance in tumorigenesis, for further RT-PCR analysis to confirm the results of the microarray data. In the figure +denotes (+H19) and –(-H19). The genes chosen were (A)-FGF18; (B)-IGFBP4; (C)-ANG; (D)-LBR; and (E)-AKT1 . The knockdown, of H19 and the RT-PCR integrity are shown in Figure 7.